Trial Profile
The beneficial effect of branched-chain amino acids with simeprevir with peginterferon alpha-2b plus ribavirin for chronic hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2018
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 20 Mar 2018 Status changed from recruiting to completed.
- 11 Mar 2015 New trial record